BioSpace News Archive

Pharm Country

The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing

Inclisiran achieved 58% LDL-C lowering with time-adjusted reductions of 56% sustained over 18 months of treatment in patients with atherosclerotic cardiovascular disease (ASCVD)

November 16, 2019
·
9 min read
Drug Development

Kiniksa Presents Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019

Rapid resolution of both reported pain and inflammation as well as improvement in quality of life scores

November 16, 2019
·
13 min read
Pharmascience Inc. contributes to the Montreal Heart Institute’s COLchicine Cardiovascular Outcome Trial (COLCOT), a landmark study to benefit cardiovascular patients and the healthcare system

The Montreal Heart Institute announced earlier the results of its COLchicine Cardiovascular Outcomes Trial

November 16, 2019
·
3 min read
Pharm Country

Caladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at American Heart Association Scientific Sessions 2019

Single administration of CLBS16 durably improves heart function and symptoms with no cell-related adverse events

November 16, 2019
·
7 min read
Drug Development

BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation

November 16, 2019
·
11 min read
Drug Development

Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma

Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, presented updated data from people with synovial sarcoma treated in the ongoing Phase 1 trial with ADP-A2M4.

November 16, 2019
·
4 min read
Colchicine significantly reduces the risk of first and total ischemic cardiovascular events by 23% and 34% respectively in addition to standard of care in patients with a recent myocardial infarction (MI)

Results simultaneously published in the New England Journal of Medicine and presented at the American Heart Association Late-Breaking Scientific Session

November 16, 2019
·
4 min read
Pharm Country

ISCHEMIA Trial Finds No Evidence of Lower Cardiac Event Rates in Patients Treated with Heart Procedures, but Better Quality of Life

A federally funded, international study found no evidence that patients with severe but stable heart disease who underwent heart procedures experienced lower rates of major, disease-related events compared to those treated with medications and lifestyle changes alone.

November 16, 2019
·
6 min read
Drug Development

CORRECTION: BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation

November 16, 2019
·
11 min read
Pharm Country

Carisma Therapeutics Announces Investor Conference Participation

Carisma Therapeutics Inc. announced that it will be participating in three upcoming investor conferences.

November 16, 2019
·
2 min read